Projected Top 3 earning drugs in 2014
Written by Alyssa Clark
1. Sovaldi; Hepatitis C
Manufactured by Gilead, this hepatitis C drug won approval last December and is set to take on the world in 2014. This drug is thought to have the most successful chance of not only providing patients with long-lasting and safe results, but is thought to be the target of a buyout by the end of 2014. Investors looking into their options for a productive and cost-effective drug, need not look any further. This drug is thought of as “one to watch” and a “blockbuster” for the upcoming year.
2. Abraxane; Breast, Lung and Pancreatic Cancer
This newly developed drug is a cancer compound that is already approved for the treatment of breast, lung and pancreatic cancer. Due to the expansion of its label and international reputation, this drug has already hit new highs for the year— and it’s only February. Celegene’s latest investment, Abraxane’s only negative set back will be its cost; the drug is estimated to cost between $6,000 and $8,000 per month, presenting a successful result, but with a very hefty price tag. After being acquired by Celegene for $3 billion in 2010, the line proved to be an easy approval for the FDA and the drug began being used almost immediately to treat those diagnosed with pancreatic cancer. The cost/benefit analysis for investors will come down to the price and how many public patients can really afford to use this kind of treatment.
3. Avastin; Lung Cancer
Roche’s mega-blockbuster drug that recently was combined with its other high-functioning drug Alimta; this new combination generated nearly $7 billion in sales last year, and is thought to rival Abraxane in its public appeal and investment potential. This drug has been one of the more consistent performers within the market, but due to the recent combination of the two successful drugs, analysts are placing this drug as one of the front-runners that may explode on the scene throughout 2014. Rivaling Abraxane for highest grossing drug of the quarter, this one is going to jump the curve and may seriously allow for multiple “cash in” opportunities this year.
Dubai's new smart neuro spinal hospital: need to know
We take a look at Dubai's new smart hospital.
What: The Neuro Spinal Hospital and Radiosurgery Centre is a new hospital featuring state-of-the-art technology for spinal, neurosurgical, neurological, orthopaedic, radiosurgery and cancer treatments. The 700 million AED hospital, (equivalent to £138 million), has 114 beds, smart patient rooms, and green spaces for patient rehabilitation, and is four times the capacity of its former premises in Jumeirah. It is also the UAE’s first hospital to have surgical robots.
Where: The hospital is located in the Dubai Science Park. Founded in 2005, Dubai Science Park is home to more than 350 companies from multinational corporations in life sciences, biotechnology and research; over 4,000 people work here each day.
Who: The UAE's Neuro Spinal Hospital and Radiosurgery Centre was first established in Jumeirah in 2002 by Dr. Abdul Karim Msaddi, as the first as the first "super-specialty" neuroscience hospital.
Why: With advanced diagnosis and robotics, the hospital will provide care across neuroscience, spine, orthopaedics and oncology for people residing in the UAE, as well as international patients.
Prof. Abdul Karim Msaddi, Chairman and Medical Director of the hospital, said: “We are proud to bring world-class healthcare services to Dubai and believe our next-generation hospital will be a game-changer for the emirate’s and the region’s medical industry.
"It will not only significantly increase the availability of specialist neuroscience and radiosurgery treatments and provide better patient care but help attract and develop local and international talent. Investing in the new centre represents our continued faith in the resilience of the region’s economy, as well as a testament to our ongoing drive towards healthcare innovation in the UAE.”